Skip to content
< Back to blog

Webinar recap: Implementing Devyser BRCA to evaluate hereditary cancer risk

Hereditary cancer

Hereditary cancer | December 16, 2024

Hereditary cancers, particularly breast and ovarian cancers, pose a significant risk for many individuals with inherited genetic mutations. Detecting these genetic variants early can profoundly affect patient outcomes, enabling timely preventive actions and tailored treatment plans. Our recent Devyser BRCA webinar, led by CARPERMOR molecular biology specialist Juan Torres Gregorio, explored how genetic testing with Devyser BRCA streamlines the detection of clinically relevant variants.  

Understanding BRCA: A gateway to cancer prevention 

BRCA1 and BRCA2 are genes with crucial roles in DNA repair and genomic stability. Mutations in these tumor-suppressor genes heighten the risk for several types of cancer, including breast and ovarian cancer. The BRCA testing process, as explained in the webinar, enables healthcare providers to detect these variants in patients with a family history of cancer or other predisposing factors. According to recent research cited during the webinar, 14% of Latin American patients diagnosed with breast and ovarian cancer carry a BRCA mutation, underlining the importance of region-specific genetic studies. 

Moving beyond traditional testing: The power of NGS 

While traditional testing methods like PCR are still in use, next-generation sequencing (NGS) offers distinct advantages. NGS screens for a broader range of mutations across entire genes and identifies copy number variations (CNVs) – a known challenge in conventional testing. Devyser BRCA capitalizes on these NGS capabilities, delivering comprehensive coverage of BRCA1 and BRCA2 and allowing for high-throughput, efficient testing. This translates into quicker, more precise genetic analysis, which is critical for early intervention in hereditary cancer cases. 

Robust validation and quality assurance 

The webinar detailed Devyser BRCA performance during the rigorous validation process. Following CAP (College of American Pathologists) guidelines, the panel demonstrated high sensitivity and specificity, with quality control measures covering every step from sample preparation to variant classification.  

Curious to learn more? Watch the full webinar on-demand to dive deeper into the analytical specifics, real-world applications, and case studies illustrating the impact of Devyser BRCA on hereditary cancer management. 

Watch the on-demand webinar now!

Disclaimer: Devyser BRCA is available as CE-IVD-marked product in the EU and countries accepting CE-IVD. Available as research use only (RUO) in all other countries.   

Contact an expert at Devyser

If you have a question, feel free to send us a message. One of our team members will get in touch with you as soon as possible.

Contact us